What is the indication for Ubrelvy (Ubrogepant)?

From the Guidelines

Ubrelvy (ubrogepant) is indicated for the acute treatment of migraine with or without aura in adults. It is not intended for migraine prevention but rather to treat migraine attacks after they have begun. The recommended dose is 50 mg or 100 mg taken orally as needed, with a maximum of 200 mg in a 24-hour period. Patients should take Ubrelvy at the first sign of a migraine attack for optimal effectiveness. If needed, a second dose may be taken at least 2 hours after the initial dose. Ubrelvy belongs to a class of medications called calcitonin gene-related peptide (CGRP) receptor antagonists, which work by blocking CGRP receptors that are involved in pain transmission during migraine attacks. This medication is particularly useful for patients who cannot take triptans due to cardiovascular contraindications or those who have not responded adequately to other acute migraine treatments. Patients should be aware that Ubrelvy may interact with certain medications, particularly strong CYP3A4 inhibitors, and dose adjustments may be necessary in these cases, as suggested by the 2023 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline for the management of headache 1. Additionally, the pharmacologic treatments of acute episodic migraine headache in outpatient settings guideline from the American College of Physicians also supports the use of ubrogepant for the acute treatment of migraine 1. The most recent evidence from 2024 further emphasizes the role of ubrogepant in acute migraine treatment, highlighting its efficacy and safety profile 1. Key points to consider when prescribing Ubrelvy include:

• Starting treatment as soon as possible after the onset of migraine symptoms
• Being aware of potential interactions with other medications
• Considering the use of Ubrelvy in patients who have contraindications to triptans or have not responded to other acute migraine treatments
• Educating patients on the proper use and potential side effects of Ubrelvy, as well as the importance of lifestyle modifications and stress management in reducing migraine frequency and severity.

From the FDA Drug Label

UBRELVY is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.

The indication for Ubrelvy (Ubrogepant) is for the acute treatment of migraine with or without aura in adults. It is not indicated for the preventive treatment of migraine 2.

• Key Points:
  • Acute treatment of migraine
  • With or without aura
  • In adults
  • Not for preventive treatment 2 2

From the Research

Indication for Ubrelvy (Ubrogepant)

• Ubrelvy (Ubrogepant) is indicated for the acute treatment of migraine headaches with or without aura in adults 3, 4, 5.
• The medication is a calcitonin gene-related peptide (CGRP) receptor antagonist, which works by blocking the CGRP receptor to alleviate migraine pain 4, 5.
• Ubrogepant is available in 50- and 100-mg tablets, with a maximum dose of 200 mg within 48 hours 4.
• The medication is effective in minimizing pain and alleviating migraine-associated symptoms such as nausea, photophobia, and sound sensitivity 4, 5.

Efficacy and Safety

• Studies have shown that Ubrogepant is effective in achieving freedom from pain and absence of the most bothersome migraine-associated symptom at 2 hours after the dose 5, 6.
• The medication has a favorable safety profile, with the most common adverse events being nausea, somnolence, and dry mouth 5, 7.
• Ubrogepant can be used in combination with triptans, and the coadministration of ubrogepant with sumatriptan was well tolerated in healthy participants and participants with migraine 7.